Solid ARR and Cash FlowBOSTON, Feb. 5, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its first fiscal quarter ended December 31, 2024."In Q1'25, we delivered solid year-over-year constant currency ARR growth of 11% and cash flow growth above 25%, which was in-line with our guidance. Our differentiated strategy leverages our unique portfolio to help product companies accelerate their time to market and manage increasing complexity. It's an exciting time because our products are ...

Wall Street analysts expect PTC Inc. (PTC) to post quarterly earnings of $0.91 per share in its upcoming report, which indicates a year-over-year decline of 18%. Revenues are expected to be $551.92 million, up 0.3% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give d ...

PTC Inc (PTC) is scheduled to report first-quarter fiscal 2025 results on Feb. 5.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.For the quarter, PTC anticipates revenues between $540 million and $570 million. Non-GAAP EPS is expected in the range of 75 cents to 95 cents.The Zacks Consensus Estimate for revenues is pegged at $551.9 million, indicating an increase of 0.3% from the year-ago reported number. The consensus estimate for earnings is pegged at 91 cents per share, down 18% ...

BOSTON, Jan. 15, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2025 first quarter results on Wednesday, February 5th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, February 5th at 5 pm Eastern Time. The earnings press release, accompanying earnings presentation, and financial data tables will be accessible prior to the conference call and webcast on the Investor Relations section of the Company's website at P ...

– Unaudited 2024 total revenue of approximately $814 million, exceeding guidance –– Four approval applications submitted to FDA in 2024 –– Global launch preparations underway for sepiapterin for PKU, a $1 billion market opportunity; CHMP opinion expected Q2 2025, U.S. approval decision in July 2025 –  – License and collaboration agreement with Novartis for PTC518 program closed – – PIVOT-HD data readout for PTC518 expected Q2 2025 –WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: ...

He also leads the investing group IPO Edge , which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to init ...

WARREN, N.J., Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PST / 2:15 p.m. EST.The presentation will be webcast live on the Events and Presentations page under the Investors section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recomme ...

Industry Overview - The fourth industrial revolution is characterized by the integration of smart digital technologies that work together iteratively in real time, greatly benefiting the manufacturing industry [16] - The first industrial revolution was driven by steam power and mechanical production, the second by electricity and mass production, and the third by the information age (semiconductors, computing, and the internet) [2] - Spending on digital transformation is expected to grow at a 16.2% compound annual growth rate from 2022 to 2027, reaching $3.9 trillion compared to $1.9 trillion in 2022 [5] PTC's Role in the Industry - PTC's software plays a pivotal role in the fourth industrial revolution, particularly through its closed-loop digital thread, which gathers data across a product's entire life cycle to improve processes iteratively [3][16] - The company's software suite includes computer-aided design (CAD), product life-cycle management (PLM), Internet of Things (IoT), augmented reality (AR), and software life cycle management (SLM) solutions [10][17] - PTC's software enables manufacturers to shorten development timelines while maintaining high quality, integrating hardware, mechanical, electronic, and embedded software processes [18] PTC's Growth Strategy - PTC is refocusing on its five key industry verticals: industrial products, aerospace and defense, electronics and technology, automaking, and medical technology and life sciences to drive ARR growth [19] - The company recently appointed Robert Dahdah, former Microsoft vice president, as chief revenue officer to lead sales and customer success for its Digital Thread group and new market strategy [13] - PTC's annual run rate (ARR), which includes subscription software, SaaS, and support contracts, continues to show double-digit growth despite economic challenges [18] Market Potential - The increasing adoption of digital technologies is expected to amplify the value PTC provides to its manufacturing customers, leading to significant growth for the company in the medium and long term [15] - Industry forecasters expect PTC to grow at a mid-teens rate over the next decade, driven by the ongoing investment in digital technology and the fourth industrial revolution [20] - Lower interest rates and a potential pick-up in industrial spending are seen as additional benefits for PTC's growth prospects [14]

- If approved, vatiquinone would be the first and only authorized therapy for children with FA -- PTC's fourth approval application submitted to FDA in 2024 -WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA)."We are excited to have reached this important milestone in the developm ...

Collaboration brings together industry leaders to advance generative AI use cases for manufacturing Codebeamer Copilot expected to simplify requirements management as part of the product development process Codebeamer Copilot beta expected to release in early 2025BOSTON, Dec. 3, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has partnered with Microsoft and Volkswagen Group to develop a generative artificial intelligence (AI) copilot based on the PTC Codebeamer® application lifecycle manage ...